ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Indiana's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2009
Meetings & Education
State Society Education Series
Articles and Blogs
Patient Advocacy Organizations
State & Federal Resources
Financial Advocacy & Patient Assistance
National Professional Organizations
Off-Label Use Literature
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Fedratinib for Intermediate-2 or High-Risk Myelofibrosis
On August 16, 2019, the Food and Drug Administration approved fedratinib (Inrebic, Impact Biomedicines, Inc.) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
The prescribing information for fedratinib includes a Boxed Warning to advise healthcare professionals and patients about the risk of serious and fatal encephalopathy, including Wernicke’s encephalopathy. Healthcare professionals are advised to assess thiamine levels in all patients prior to starting fedratinib, periodically during treatment, and as clinically indicated. If encephalopathy is suspected, fedratinib should be immediately discontinued and parenteral thiamine initiated.
Read FDA announcement